ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
A CLINICAL-TRIAL OF IMMUNOSUPPRESSIVE THERAPY FOR MYOCARDITIS
Author(s): MASON JW, OCONNELL JB, HERSKOWITZ A, ROSE NR, MCMANUS BM, BILLINGHAM ME, MOON TE, COSTANZO MR, GRADY K, KANTROWITZ NE, ZELDIS SM, KANE S, COGLIANESE ME, TOMEO C, BACON K, MCLAUGHLIN PR, LIU P, ROSS B, PALACIOS IF, DEC W, BLOCK B, COCCASPOFFARD D, YOUNG JB, LEON C, CASTA R, KINGRY C, STRICKMAN NE, HARLAN M, FOWLER N, ENGEL P, NUNN N, DAS SK, SUHY P, KLINE E, GILLES AJ, FRENCH WJ, SKINNER A, UNVERFERTH DV, SARLING R, NEWTON P, WOODINGSCOTT M, UNTEREKER WJ, POLL D, HOFFMAN K, FRANK J, FOWLES R, MILLAR K, FREEDMAN L, LYVER S, LATHAM R, PEEPLES R, GOLDENBERG IF, HUNN D, ANDERSON P, WEISS MB, TRUELIEB N, HOSENPUD J, CONNER R, BROWN LJ, RAMANATHAN KB, POUNDERS C, MILLS M, KANTOR K, ABELMANN WH, FLAHERTY A, THORP K, STRAIN J, VIRZI P, GRAYESKI A, KELLY A, HOBBS RE, PELEGRIN D, COHEN M, HAWKINS L, KOSTUK WJ, KENNEDY R, HAGER WD, DOUGHERTY J, RIBA A, LARKIN S, KEARNY L, DAVIES RA, DROUIN K, MATSUMORI A, GROSE RM, LEVINE B, URETSKY BF, MURALI S, BETSCHART A, WILLIAMS GA, MILLER L, WITTRY S, HAGAN AD, DURHAM J, SHABETAI R, CREMO R, MCMANUS BM, SEARS T, ARTEAGA W
Source: NEW ENGLAND JOURNAL OF MEDICINE    Volume: 333    Issue: 5    Pages: 269-275    Published: AUG 3 1995  
Times Cited: 427     References: 26     
Abstract: Background. Myocarditis is a serious disorder, and treatment options are limited, This trial was designed to determine whether immunosuppressive therapy improves left ventricular function in patients with myocarditis.

Methods. We randomly assigned 111 patients with a histopathological diagnosis of myocarditis and a left ventricular ejection fraction of less than 0.45 to receive conventional therapy alone or combined with a 24-week regimen of immunosuppressive therapy, Immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine, The primary outcome measure was a change in the left ventricular ejection fraction at 28 weeks.

Results. In the group as a whole, the mean (+/-SE) left ventricular ejection fraction improved from 0.25+/-0.01 at base line to 0.34+/-0.02 at 28 weeks (P<0.001), The mean change in the left ventricular ejection fraction at 28 weeks did not differ significantly between the group of patients who received immunosuppressive therapy (a gain of 0.10; 95 percent confidence interval, 0.07 to 0.12) and the control group (a gain of 0.07; 95 percent confidence interval, 0.03 to 0.12), A higher left ventricular ejection fraction at base line, less intensive conventional drug therapy at base line, and a shorter duration df disease, but not the treatment assignment, were positive independent predictors of the left ventricular ejection fraction at week 28, There was no significant difference in survival between the two groups (P=0.96), The mortality rate for the entire group was 20 percent at 1 year and 56 percent at 4.3 years, features suggesting an effective inflammatory response were associated with less severe initial disease.

Conclusions. Our results do not support routine treatment of myocarditis with immunosuppressive drugs. Ventricular function improved regardless of whether patients received immunosuppressive therapy, but long-term mortality was high.

Document Type: Article
Language: English
Reprint Address: MASON, JW (reprint author), UNIV UTAH, MED CTR, DIV CARDIOL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA
Addresses:
1. UNIV MISSISSIPPI, DEPT MED, JACKSON, MS USA
2. JOHNS HOPKINS UNIV, DIV CARDIOL, BALTIMORE, MD USA
3. JOHNS HOPKINS UNIV, DEPT MOLEC MICROBIOL & IMMUNOL, BALTIMORE, MD USA
4. UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER, BC CANADA
5. STANFORD UNIV, DEPT PATHOL, STANFORD, CA USA
6. UNIV ARIZONA, DEPT FAMILY & COMMUNITY MED, TUCSON, AZ USA
Publisher: MASS MEDICAL SOC, 10 SHATTUCK, BOSTON, MA 02115
Subject Category: Medicine, General & Internal
IDS Number: RL694
ISSN: 0028-4793
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo